Liquidia Technologies Inc. (LQDA) and Synlogic Inc. (NASDAQ:SYBX) Comparison side by side

Liquidia Technologies Inc. (NASDAQ:LQDA) and Synlogic Inc. (NASDAQ:SYBX) compete with each other in the Biotechnology sector. We will analyze and contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Liquidia Technologies Inc. 1.78M 90.44 39.39M -3.40 0.00
Synlogic Inc. 2.50M 78.27 50.22M -2.04 0.00

Table 1 highlights Liquidia Technologies Inc. and Synlogic Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Liquidia Technologies Inc. and Synlogic Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Liquidia Technologies Inc. -2,212.92% 0% 0%
Synlogic Inc. -2,008.80% -36.2% -32.3%

Liquidity

The Current Ratio and Quick Ratio of Liquidia Technologies Inc. are 5.6 and 5.6 respectively. Its competitor Synlogic Inc.’s Current Ratio is 14.9 and its Quick Ratio is 14.9. Synlogic Inc. can pay off short and long-term obligations better than Liquidia Technologies Inc.

Insider and Institutional Ownership

Institutional investors held 44.4% of Liquidia Technologies Inc. shares and 82.1% of Synlogic Inc. shares. Liquidia Technologies Inc.’s share held by insiders are 1.1%. Competitively, insiders own roughly 0.2% of Synlogic Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Liquidia Technologies Inc. -0.1% -0.2% -31.03% -48.27% 0% -54.43%
Synlogic Inc. 0.12% 3.77% -19.34% 3.38% -22% 17.83%

For the past year Liquidia Technologies Inc. had bearish trend while Synlogic Inc. had bullish trend.

Summary

Synlogic Inc. beats on 6 of the 10 factors Liquidia Technologies Inc.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.